Objective To observe the therapeutic effect of Piwei Peiyuan Decoction(PWPYD)in treating chronic atrophic gastritis patients with Pi-Wei weakness type accompanied with intestinal metaplasia.Methods A total of 100 chro...Objective To observe the therapeutic effect of Piwei Peiyuan Decoction(PWPYD)in treating chronic atrophic gastritis patients with Pi-Wei weakness type accompanied with intestinal metaplasia.Methods A total of 100 chronic atrophic gastritis patients with Pi-Wei weakness type accompanied with intestinal metaplasia were included in this study from June 2022 to December 2023 at the Second Affiliated Hospital of Anhui University of Chinese Medicine.Totally 96 patients met the inclusion criteria and were randomly assigned to the control group and the treatment group,48 cases in each group.The patients in the treatment group were treated with PWPYD,and those in the control group were treated with folic acid tablets.The treatment course lasted for 24 weeks.The changes of pathological scores,Chinese medicine(CM)symptom scores,and gastroscopic scores,serum pepsinogen I(PG I),pepsinogen II(PG II),gastrin-17(G-17),interleukin-6(IL-6),IL-10,and tumor Necrosis factor-Alpha(TNF-α)levels were observed before and after treatment between the two groups.Meanwhile,Western Blot and RT-qPCR were used to detect the levels of cystine glutamate reverse transporter(xCT),glutathione eroxidase 4(GPX4),and peroxisome proliferator activated receptorα(PPARα)expressions.Results Compared with baseline,pathological scores,CM symptom scores,and gastroscopic scores decreased in the two group after treatment(P<0.05).The serum PG I,PG II,G-17,and IL-10 expression levels increased(P<0.05),and the serum IL-6 and TNF-αexpression levels decreased(P<0.05).The protein and mRNA levels of xCT,GPX4,and PPARαin the focal tissue decreased(P<0.05).Compared with the control group after treatment,pathological scores and gastroscopic scores of mucous membrane color,mucous membrane texture decreased(P<0.05),CM symptom scores of gastric distension and fullness,gastric pain,low food intake and nausea,fatigue and weakness,and shortness of breath and laziness decreased in the treatment group(P<0.05).The expression levels of serum PG I,G-17,IL-6,IL-10,and TNF-αin the treatment group were better than in the control group(P<0.05).The protein and mRNA levels of xCT,GPX4,and PPARαin lesion tissues in the treatment group were lower than those in the control group(P<0.05).Conclusion By regulating the expression levels of serum inflammatory factors and the protein and mRNA expression levels of xCT,GPX4,and PPARαin the lesion tissue,PWPYD can improve the clinical symptoms and pathological changes of the gastric mucosa of the patients,and improve their quality of life.展开更多
文摘Objective To observe the therapeutic effect of Piwei Peiyuan Decoction(PWPYD)in treating chronic atrophic gastritis patients with Pi-Wei weakness type accompanied with intestinal metaplasia.Methods A total of 100 chronic atrophic gastritis patients with Pi-Wei weakness type accompanied with intestinal metaplasia were included in this study from June 2022 to December 2023 at the Second Affiliated Hospital of Anhui University of Chinese Medicine.Totally 96 patients met the inclusion criteria and were randomly assigned to the control group and the treatment group,48 cases in each group.The patients in the treatment group were treated with PWPYD,and those in the control group were treated with folic acid tablets.The treatment course lasted for 24 weeks.The changes of pathological scores,Chinese medicine(CM)symptom scores,and gastroscopic scores,serum pepsinogen I(PG I),pepsinogen II(PG II),gastrin-17(G-17),interleukin-6(IL-6),IL-10,and tumor Necrosis factor-Alpha(TNF-α)levels were observed before and after treatment between the two groups.Meanwhile,Western Blot and RT-qPCR were used to detect the levels of cystine glutamate reverse transporter(xCT),glutathione eroxidase 4(GPX4),and peroxisome proliferator activated receptorα(PPARα)expressions.Results Compared with baseline,pathological scores,CM symptom scores,and gastroscopic scores decreased in the two group after treatment(P<0.05).The serum PG I,PG II,G-17,and IL-10 expression levels increased(P<0.05),and the serum IL-6 and TNF-αexpression levels decreased(P<0.05).The protein and mRNA levels of xCT,GPX4,and PPARαin the focal tissue decreased(P<0.05).Compared with the control group after treatment,pathological scores and gastroscopic scores of mucous membrane color,mucous membrane texture decreased(P<0.05),CM symptom scores of gastric distension and fullness,gastric pain,low food intake and nausea,fatigue and weakness,and shortness of breath and laziness decreased in the treatment group(P<0.05).The expression levels of serum PG I,G-17,IL-6,IL-10,and TNF-αin the treatment group were better than in the control group(P<0.05).The protein and mRNA levels of xCT,GPX4,and PPARαin lesion tissues in the treatment group were lower than those in the control group(P<0.05).Conclusion By regulating the expression levels of serum inflammatory factors and the protein and mRNA expression levels of xCT,GPX4,and PPARαin the lesion tissue,PWPYD can improve the clinical symptoms and pathological changes of the gastric mucosa of the patients,and improve their quality of life.
